

Protein kinase C α stimulates hypoxia-induced pulmonary artery smooth muscle cell proliferation in rats through activating the extracellular signal-regulated kinase 1/2 pathway

RUI JIANG^{1,2}, YIWEI SHI^{3*}, CHAO ZENG^{1,2}, WENYAN YU⁴, AIZHEN ZHANG² and YONGCHENG DU^{2*}

¹Shanxi Medical University, Taiyuan, Shanxi 030001; ²Department of Respiratory and Critical Care Medicine, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi 030012;

³Department of Respiratory and Critical Care Medicine, Shanxi Medical University Affiliated First Hospital, Taiyuan, Shanxi 030001; ⁴Respiratory Department, Central Hospital of Zibo, Zibo, Shandong 255036, P.R. China

Received September 27, 2016; Accepted July 18, 2017

DOI: 10.3892/mmr.2017.7478

Abstract. Hypoxic pulmonary hypertension (HPH) may contribute to vascular remodeling, and pulmonary artery smooth muscle cell (PASMC) proliferation has an important role in this process. However, no relevant information concerning the role and mechanism of protein kinase C (PKC) α in hypoxia-induced rat PASMC proliferation has been elucidated. The present study aimed to further investigate this by comparison of rat PASMC proliferation among normoxia for 72 h (21% O₂), hypoxia for 72 h (3% O₂), hypoxia + promoter 12-myristate 13-acetate control, hypoxia + safinolol control, hypoxia + PD98059 control and hypoxia + U0126 control groups. The present study demonstrated that protein expression levels of PKC α in rat PASMCs were elevated. In conclusion, through activating the extracellular signal-regulated 1/2 signaling pathway, PKC α is involved in and initiates PASMC proliferation, thus bringing about pulmonary artery hypertension. These results add to the understanding of the mechanism PKC α in PH formation and lays a theoretical basis for prevention as well as treatment of HPH.

Introduction

Pulmonary hypertension (PH) is a pathophysiological syndrome caused by heterogeneous diseases and diverse pathogenesis, with the dominant feature of continuous increase of pulmonary vascular resistance. Characterized by its clinical manifestations of increased load behind right ventricle, decreased activity endurance and even death out of heart failure, PH is a severe chronic pulmonary circulatory illness which could contribute to potential fatality. Provided that no effective treatment is conducted, the prognosis for majority of PH patients will be extremely poor, with ~15% mortality rate within 1 year on modern therapy (1-4).

Hypoxic pulmonary hypertension (HPH) is a clinically common type of PH, with frequent occurrence in various chronic pulmonary ailments. With interaction of long-term anoxia, chronic inflammation, a variety of active vascular substances and growth factors, the structure of pulmonary vessels may undergo transformation, resulting in vascular remodeling. On the other hand, remodeling of pulmonary arterial smooth muscle cells (PASMCs) is a key feature known to result from an imbalance between apoptosis and cell proliferation (5).

As a member of the family of serine/threonine protein kinases, protein kinase C (PKC) was first discovered by Nishizuka in 1997 (6). So far, at least 11 subtypes of PKC have been isolated and purified from different species and tissues of tissue organs (7). According to dissimilarity of molecular structure and sensitivity to activators, PKC subtypes could be grouped into three categories involving the conventional (cPKC α , β I, β II and γ), the novel (nPKC δ , ϵ , η and θ) as well as the atypical (aPKC λ , μ and ζ). The classical PKCs are diacylglycerol (DAG) and Ca²⁺-dependent enzymes; whereas, the novel PKCs require DAG, but not calcium, for activation. The atypical are not responsive to activation by DAG or calcium, but are activated by other lipid-derived second messengers (8).

PKC may exist in almost all the tissue cells, including PASMCs (9,10). In addition, PKC not only participates in the process of cell growth, differentiation, apoptosis and contraction of smooth muscle cells (SMCs), but also serves

Correspondence to: Professor Yongcheng Du, Department of Respiratory and Critical Care Medicine, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, 29 Shuangtasi Street, Taiyuan, Shanxi 030012, P.R. China
E-mail: 26688833@qq.com

Professor Yiwei Shi, Department of Respiratory and Critical Care Medicine, Shanxi Medical University Affiliated First Hospital, 85 South Jiefang Road, Yingze, Taiyuan, Shanxi 030001, P.R. China
E-mail: chinasyw225@163.com

*Contributed equally

Key words: hypoxia-induced factor, pulmonary hypertension, protein kinase C α , extracellular signal-regulated kinase1/2, pulmonary artery smooth muscle cell

a significant part in signal transduction pathways mediated by hormones, neurotransmitters, growth factors and antigens (11,12). PKC has been reported to act as a signaling mediator in hypoxia-induced cell proliferation (13). Recently, PKC α has been demonstrated to serve a vital role in proliferation of diverse cells, including PASMCs (14-17). An study investigating ox pulmonary arterial smooth muscle cells demonstrated that PKC initiates and promotes PASMC proliferation (14). In a study of rat thoracic aortic smooth muscle cells, however, Sasaguri *et al* (18) revealed that PKC activation inhibits SMC proliferation. These studies suggested that PKC and its mediated cell signaling pathways may occupy an important position in SMC proliferation, but with inconsistent and conflicting findings.

To investigate hypoxia-induced PASMC proliferation, the present study aimed to establish an external model of hypoxic pulmonary hypertension and to observe the change and underlying molecular mechanism of PKC α expression in hypoxia-induced rat PASMCs, as well as its impact upon PASMC proliferation. The present study may further uncover the molecular mechanism of PH pulmonary vascular remodeling, providing a theoretical basis for its prevention and treatment.

Materials and methods

Animals and agents. A total of 20 adult rats (age, 8 weeks; weight, ~200 g) purchased from the Experimental Animal Center of Shanxi Medical University (Taiyuan, China) were maintained in a temperature-(22°C) and humidity (between 60 and 65%)-controlled room on a 12-h light/dark cycle with free access to food and water for 1 week prior to use. All procedures were approved by the Animal Management Guidelines of the Ministry of Health of the People's Republic of China, in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Dulbecco's modified Eagle's medium (DMEM) and 20% fetal bovine serum (FBS) were obtained from Hyclone; GE Healthcare Life Sciences (Logan, UT, USA). Monoclonal antibodies against ERK (cat. no. 9102) and phosphorylated (p)-ERK (cat. no. 9101) were from Cell Signaling Technology, Inc. (Beverly, MA, USA). Polyclonal antibodies against smoothlin (cat. no. sc-20481), PKC α (cat. no. sc-208) were from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Polyclonal antibody against β -actin (cat. no. AP0060) was from Bioworld Technology, Co., Ltd. (Nanjing, China). Polyclonal antibodies against smooth muscle myosin heavy chain (cat. no. ab53219) were obtained from Abcam (Cambridge, MA, USA).

Isolation and culture of PASMCs. Rat PASMCs were isolated and cultured in accordance with previously described methods (19). Rats were anaesthetized by intraperitoneal injection of pentobarbital sodium (Sinopharm Chemical Reagent Co., Ltd., Beijing, China; 50 mg/kg body weight), then the main trunk of pulmonary arteries and the right and left branches were isolated under a dissecting light microscope (Olympus Corporation, Tokyo, Japan). After connective tissues of arteries were cleaned and vessels cut open longitudinally, luminal endothelia were removed by gentle scraping with cotton swabs. The isolated pulmonary arteries were dissected into

small pieces of 1x1 mm, maintained in DMEM supplemented with 20% FBS and incubated in a humidified atmosphere with 5% CO₂ at 37°C. Culture medium was changed twice per week and cells were harvested with trypsin (0.25%; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing EDTA. Passages ranging from 4 to 6 were used for all experiments, which were divided into three groups: Normoxia, hypoxia and control. In the normoxia group, PASMCs were placed at 37°C in a humidified atmosphere containing 5% CO₂. In the hypoxia group, PASMCs were placed into three-gas chambers containing 3% O₂, 5% CO₂ and 92% N₂ for 24, 48 and 72 h, respectively. In the control group, cells were pre-treated with drugs (12-myristate 13-acetate, safinolol, PD98059 and U0126) and placed into three-gas chambers containing 3% O₂, 5% CO₂ and 92% N₂ for 72 h. Prior to exposure to hypoxia or treatment, cells were incubated in DMEM with free FBS for 24 h and then exposed to hypoxia or treated in DMEM supplemented with 2% FBS.

Immunofluorescence staining of PASMCs. PASMCs were plated in glass chambers, fixed with 4% paraformaldehyde for 10 min, and added to 0.2% permeable Triton X-100 for 15 min. Following three washes in PBS, cells were blocked with goat serum (Solarbio, Beijing, China) for 1 h, followed by incubation with anti-smoothlin (1:100) and anti-smooth muscle heavy chain (1:80) primary antibodies overnight at 4°C. Cells were then washed with PBS three times, followed by incubation with fluorescein isothiocyanate-conjugated secondary antibody (cat. no. A16000; dilution, 1:500; Thermo Fisher Scientific, Inc.) and tetramethylrhodamine-conjugated secondary antibody (cat. no. A16040; dilution, 1:500; Thermo Fisher Scientific, Inc.) for 1 h in the dark. Following three washes with PBS, nuclei were stained with DAPI for 10 min and observed using confocal laser scanning microscope. All the aforementioned procedures were performed at room temperature.

Cell proliferation assay. PASMCs at a density of 5x10³ cells were plated into 96-well glass chamber plates. Cell proliferation in the normoxia, hypoxia and control groups were measured. MTT (20 μ l; 5 mg/ml) was added to each well and the slides were incubated in a humidified incubator with 5% CO₂ at 37°C for 4 h. At the end of incubation, the supernatant was removed and dimethyl sulfoxide (DMSO; 150 μ l/well) was added to the plates to solubilize for 10 min. The optical densities were determined using a multi-well scanning spectrophotometer (Spectra Max Plus 384, Molecular Devices, LLC, Sunnyvale, CA, USA) at 490 nm.

Western blot analysis. After various treatments, cells were washed three times in cold PBS, harvested and scraped with cell lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) for 2 h at 4°C. The lysates were then centrifuged at 13,000 x g for 20 min at 4°C, the supernatants collected and the total protein concentrations were determined by the Bicinchoninic Acid Protein Assay kit (Beyotime Institute of Biotechnology, Shanghai, China) following the manufacturer's protocol. Equal amounts of proteins (30 μ g) were separated by 10% SDS-PAGE, and then transferred to polyvinylidene difluoride membranes. After blocking with




Figure 1. Rat PASMCs stain positively for smooth muscle markers. PASMCs were stained with (A) DAPI, (B) anti-smoothlin and (C) anti-smooth muscle heavy chain. (D) Merged overlay of parts A-C. Magnification, x600. PASMCs, pulmonary arterial smooth muscle cells.

5% bull serum albumin (Solarbio) at room temperature for 1 h, membranes were incubated overnight at 4°C with antibodies specific for rabbit anti-p-ERK1/2 (1:1,000), rabbit anti-ERK (1:1,000), rabbit anti-PKC α (1:1,000) and rabbit anti- β -actin (1:2,000). Subsequently, the membranes were incubated with a goat anti-rabbit peroxidase-conjugated IgG secondary antibody (cat. no. ZB-2301; dilution, 1:5,000; ZSGB-BIO, Beijing, China) for 1 h at room temperature. The expressed protein amount was determined through p-ERK1/2/ERK1/2 for ERK1/2 and PKC α / β -actin for PKC α . Proteins were visualized using enhanced chemiluminescence (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Proteins were quantified using a Gel Doc XR system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using Quantity One software (version 4.62; Bio-Rad Laboratories, Inc.).

Drugs. The following drugs were used for the hypoxia treated control cells. Prior to hypoxic treatment, cells were treated with the PKC α promoter 12-myristate 13-acetate (PMA; 0.4 mM; Alomone Labs, Israel), the PKC α special inhibitor safinol (0.6 mM; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), the extracellular signal-regulated kinase kinase

(MEK1/2) inhibitor PD98059 (20 mM, Cell Signaling Technology, Inc.) or U0126 (5 mM, Cell Signaling Technology, Inc.) and incubated in a humidified atmosphere with 5% CO₂ at 37°C for 30 min one time.

Statistical analysis. Data are expressed as mean $\pm$ standard deviation. Comparisons between two groups was made with an unpaired two-tailed Student's t-test. Comparisons between multiple groups was made with a one-way analysis of variance followed by Dunnett or Tukey test. SPSS software, version 20.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analysis. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Activation of hypoxia on PASMC proliferation. Immunofluorescence staining determined that PASMCs stain positively for smooth muscle markers (Fig. 1). MTT demonstrated that the optical densities (ODs) of cells exposed to hypoxia with 3% O₂ for 24, 48 and 72 h, respectively, were significantly increased, compared with cells exposed to normoxia with 21% O₂ for 24, 48 and 72 h (Fig. 2A). The




Figure 2. Expression of PKC α protein in hypoxia-induced PASM proliferation. (A) MTT assay of PASM proliferation. * $P < 0.05$ vs. normoxia; ** $P < 0.05$ vs. 24 h hypoxia. (B) Identification of the PKC α isoform in rat PSMCs. Lane 1, rat PSMCs; lane 2, rat brain. (C) Representative western blot images and (D) quantification of PKC α protein expression levels following hypoxia. * $P < 0.05$ vs. normoxia. (E) Hypoxia-induced PSMCs proliferation was stimulated by PKC promoter PMA and blocked by PKC α special inhibitor safinol. * $P < 0.05$ vs. normoxia; ** $P < 0.05$ vs. hypoxia. Data are presented as the mean $\pm$ standard deviation of three independent experiments. PSMCs, pulmonary artery smooth muscle cells; PKC α , protein kinase C α .

mean OD values of cells exposed to normoxia for 24, 48 and 72 h were 0.152 ± 0.006 , 0.145 ± 0.003 and 0.158 ± 0.005 , respectively; however, the OD values of cells exposed to hypoxia for 24, 48 and 72 h were 0.191 ± 0.014 , 0.250 ± 0.060 and 0.359 ± 0.032 , respectively (Fig. 2A). Compared with cells exposed to hypoxia for 24 h, MTT absorbance of PSMCs in hypoxic exposure for 72 h was significantly increased ($P < 0.05$; Fig. 2A).

Upregulation of PKC α in hypoxia-induced PSMCs. The results of western blotting demonstrated that PKC α (80 kD) was present in normal rat PSMCs (Fig. 2B). As presented in Fig. 2C and D, PKC α protein expression levels in hypoxic group for 24, 48 and 72 h were 0.336 ± 0.160 , 0.656 ± 0.085 and 0.808 ± 0.098 , respectively. On the other hand, PKC α protein levels in cells exposed to normoxia for 72 h were 0.290 ± 0.013 . Compared with the 72-h normoxia group, PKC α protein expression levels in PSMCs exposed to hypoxia were markedly increased in a time-dependent manner ($P < 0.05$).

PASM proliferation induced by PKC α . To examine the role of PKC α in hypoxia-induced proliferative responses, greatly proliferated PSMCs in hypoxia for 72 h were selected, which were treated with a PKC α promoter (PMA) and inhibitor (safingol). According to the MTT findings, the mean OD values in the 72-h normoxia, 72-h hypoxia, hypoxic PMA control and hypoxic safingol groups were demonstrated to be 0.187 ± 0.037 , 0.529 ± 0.015 , 0.587 ± 0.044 and 0.426 ± 0.033 , respectively (Fig. 2E). In addition, the OD value in the hypoxic PMA control group was significantly increased compared with the hypoxia group ($P < 0.05$), whereas the OD value in the hypoxic safingol group was lower than that in hypoxic PMA control ($P < 0.05$; Fig. 2E).

PASM proliferation activated by hypoxia through ERK1/2 phosphorylation. To determine the cellular pathway that may be involved in the PASM proliferation process, the present study evaluated the possible modulation of ERK1/2 in signaling by western blotting and MTT. According to the




Figure 3. Expression of ERK1/2 protein in hypoxia-induced PAMSC proliferation. (A) Representative western blot images and (B) quantification of ERK1/2 phosphorylation in rat PAMSCs. (C) MTT assay of hypoxia-induced PAMSC proliferation following treatment with the extracellular signal-regulated kinase kinase 1/2 inhibitors PD98059 and U0126. (D) Representative western blot images and (E) quantification of ERK1/2 phosphorylation following treatment with PMA and safinigol after hypoxia exposure for 72 h. Data are presented as the mean $\pm$ standard deviation * $P < 0.05$ vs. normoxia; # $P < 0.05$ vs. hypoxia. PAMSCs, pulmonary artery smooth muscle cells; p, phosphorylated; ERK1/2, extracellular signal-regulated kinase 1/2; PMA, promoter 12-myristate 13-acetate.

western blotting results, p-ERK1/2 expression levels in cells exposed to hypoxia for 24, 48 and 72 h were 0.130 ± 0.035 , 0.246 ± 0.083 and 0.291 ± 0.054 , respectively; compared with cells exposed to normoxia for 72 h, which was 0.160 ± 0.053 (Fig. 3A and B). Compared with the 72-h normoxia group, p-ERK1/2 expression in PAMSCs after exposure to hypoxia for 48 and 72 h was markedly upregulated ($P < 0.05$, Fig. 3A and B). When PAMSCs exposed to hypoxia for 72 h were pretreated with the MEK1/2 inhibitor PD98059 or U0126, the mean OD values in the normoxia 72 h, hypoxia 72 h, hypoxic PD98059 control and hypoxic U0126 control groups were 0.187 ± 0.017 , 0.529 ± 0.015 , 0.489 ± 0.011 and 0.306 ± 0.004 , respectively. Compared with the hypoxia for 72 h group, the mean OD values in the hypoxic PD98059 control and hypoxic U0126 control groups were significantly attenuated ($P < 0.05$; Fig. 3C).

ERK1/2 phosphorylation stimulated by PKC α . To investigate a potential association between PKC α and ERK1/2, the present study tested the modulation of ERK1/2 expression through hypoxic PAMSCs pretreated with a PKC α promoter

and inhibitor. Western blotting results indicated that p-ERK1/2 protein expression levels in the normoxia for 72 h, hypoxic PMA control and hypoxic safinigol control groups were demonstrated to be 0.437 ± 0.042 , 0.558 ± 0.039 and 0.311 ± 0.082 , respectively. p-ERK1/2 protein expression levels in the presence of the PKC α promoter was significantly increased compared with the other two hypoxic groups ($P < 0.05$). Compared with the other two groups, ERK1/2 phosphorylation in the presence of PKC α inhibitor was greatly reduced ($P < 0.05$, Fig. 3D and E).

Discussion

The present study primarily demonstrated that PKC α was upregulated in hypoxia-induced rat PAMSC proliferation, and through activation of ERK1/2 phosphorylation, upregulated PKC α induced the proliferation of PAMSCs, thus contributing to the occurrence of pulmonary artery hypertension.

Chronic hypoxic pulmonary hypertension is a common clinical problem, which has an association with increased vascular tone, and imbalance between proliferation and apoptosis of PAMSCs (20,21). By MTT assay to determine PAMSC

proliferation, the present study demonstrated that hypoxia may induce PSMC proliferation, which is in consistent with findings by Preston *et al* and Li *et al* (22,23).

As a type of protein kinase, PKC is expressed in many tissue cells. To date, at least 11 subtypes of PKC have been identified, among which each type has a different function. As a classical subtype of PKC, PKC α is widely distributed and present in all the tissues, and has a connection with cell apoptosis, proliferation and migration (24). Although PKC α has been reported to serve an important role in cell proliferation, including in PSMCs, there is still a lack of research on the association between PKC α subtypes and signal transduction pathways in hypoxia-induced PSMC proliferation.

Using western blotting in the present study, PKC α was demonstrated to be present in rat PSMCs. In comparison, the presentation of various PKC subtypes including α , β and γ has been validated in a study by Barman *et al* (25). Through further investigation, the present study demonstrated that the expression level of PKC α in hypoxia-induced PSMCs was increased. In addition, the PKC α special inhibitor safinol suppressed hypoxia-induced PSMC proliferation, and the PKC α promoter PMA significantly increased proliferation. Therefore, it may be hypothesized that the promotion of PKC α expression levels serve a vital role in hypoxia-induced PSMC proliferation. Dempsey *et al* (26) demonstrated that hypoxia might activate PKC in neonatal bovine PSMCs, and the activated PKC could foster SMC proliferation through stimulating growth factors such as insulin-like growth factor-1. In addition, PKC with PKC α in particular has been demonstrated to serve a critical part in hypoxia and mitogen-induced PSMC proliferation (27). Furthermore, hypoxia-activated PKC in PSMCs has also been identified to be involved in hypoxia-induced PSMC proliferation, thus participating in the formation of hypoxic PH (28). The findings resulting from the present study fit in with those reported in the aforementioned investigations.

The mitogen-activated protein kinase (MAPK) family is comprised of ERK1/2, c-Jun N-terminal kinase (JNK) and p38 MAPK. MAPK has been reported to exhibit a distinct increase of activation in chronic hypoxic pulmonary arteries (29-31). In recent years, ERK1/2 has been identified to be activated by a variety of extracellular stimuli, and is involved in hypoxia-induced PSMC proliferation (20,22,23,32-34). PD98059 and U0126 are universally used as MEK1/2 inhibitors, the role of which is to inhibit mitochondrial metabolism, thus using up p-ERK. With ERK1/2 being the only known MEK1/2 downstream substrate (21), PD98059 and U0126 were used to block ERK1/2. In the present study, PSMC proliferation was markedly increased with exposure to hypoxia for 48 and 72 h, and p-ERK1/2 expression was also significantly increased. However, PD98059 and U0126 markedly weakened this proliferative response, which suggested that hypoxia may activate ERK1/2, thus promoting PSMC proliferation. Therefore, ERK1/2 may serve a vital part in hypoxia-induced PSMC proliferation.

It has been reported that activated PKC α induces the proliferation of capillary endothelial cells through the ERK1/2 signaling pathway (35). Another investigation demonstrated that activated PKC α in human saphenous vein SMCs

strengthened the activity of MAPKs, which could contribute to cell proliferation (36). However, relevant information concerning the role and mechanism of PKC α in PH-induced PSMCs proliferation is not yet available. The present study demonstrated that PMA-induced PKC α activation upregulated the expression of p-ERK1/2, thus increasing PSMC proliferation. On the other hand, the PKC α inhibitor safinol may inhibit ERK1/2 phosphorylation, suppressing PSMC proliferation. Therefore, increased expression of PKC α may activate ERK1/2, leading to PSMC proliferation and PH formation.

In conclusion, protein expression levels of PKC α in rats were upregulated in hypoxia-induced rat PSMCs. Through activating ERK1/2, PKC α served part in PSMC proliferation, which adds to the understanding of its mechanism in PH formation and lays a theoretical basis for prevention as well as treatment of HPH. Whether PKC α could be considered as a target for PH treatment in the future still requires further studies on the role of other subtypes in PH formation. Limitations of the present study lie in that early pathological variations of PH are primarily involved in peripheral pulmonary artery. The present study would be of much more significance if distal PSMCs could be obtained.

Acknowledgements

The present study work was supported by the Natural Science Foundation of Shanxi Province of China (grant no. 201601D011110).

References

1. Hoette S, Jardim C and Souza Rd: Diagnosis and treatment of pulmonary hypertension: An update. *J Bras Pneumol* 36: 795-811, 2010 (In English, Portuguese).
2. Shi Y, Wang C, Han S, Pang B, Zhang N, Wang J and Li J: Determination of PKC isoform-specific protein expression in pulmonary arteries of rats with chronic hypoxia-induced pulmonary hypertension. *Med Sci Monit* 18: BR69-BR75, 2012.
3. Nie X, Shi Y, Yu W, Xu J, Hu X and Du Y: Phosphorylation of PTEN increase in pathological right ventricular hypertrophy in rats with chronic hypoxia induced pulmonary hypertension. *Chin Med J (Engl)* 127: 338-342, 2014.
4. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, *et al*: ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the pulmonary hypertension association. *J Am Coll Cardiol* 53: 1573-1619, 2009.
5. Wang S, Wang Y, Jiang J, Wang R, Li L, Qiu Z, Wu H and Zhu D: 15-HETE protects rat pulmonary arterial smooth muscle cells from apoptosis via the PI3K/Akt pathway. *Prostaglandins Other Lipid Mediat* 91: 51-60, 2010.
6. Hurley JH, Newton AC, Parker PJ, Blumberg PM and Nishizuka Y: Taxonomy and function of C1 protein kinase C homology domains. *Protein Sci* 6: 477-480, 1997.
7. Nitti M, Pronzato MA, Marinari UM and Domenicotti C: PKC signaling in oxidative hepatic damage. *Mol Aspects Med* 29: 36-42, 2008.
8. Fan HC, Fernandez-Hernando C and Lai JH: Protein kinase C isoforms in atherosclerosis: Pro- or anti-inflammatory? *Biochem Pharmacol* 88: 139-149, 2014.
9. Haller H, Baur E, Quass P, Behrend M, Lindschau C, Distler A and Luft FC: High glucose concentrations and protein kinase C isoforms in vascular smooth muscle cells. *Kidney Int* 47: 1057-1067, 1995.

10. Webb BL, Lindsay MA, Seybold J, Brand NJ, Yacoub MH, Haddad EB, Barnes PJ, Adcock IM and Giembycz MA: Identification of the protein kinase C isoenzymes in human lung and airways smooth muscle at the protein and mRNA level. *Biochem Pharmacol* 54: 199-205, 1997.
11. Newton AC: Protein kinase C: Structure, function, and regulation. *J Biol Chem* 270: 28495-28498, 1995.
12. Throckmorton DC, Packer CS and Brophy CM: Protein kinase C activation during Ca^{2+} -independent vascular smooth muscle contraction. *J Surg Res* 78: 48-53, 1998.
13. Zhang H, Okamoto M, Panzhinskiy E, Zawada WM and Das M: PKC δ /midkine pathway drives hypoxia-induced proliferation and differentiation of human lung epithelial cells. *Am J Physiol Cell Physiol* 306: C648-C658, 2014.
14. Agbani EO, Coats P, Mills A and Wadsworth RM: Peroxynitrite stimulates pulmonary artery endothelial and smooth muscle cell proliferation: Involvement of ERK and PKC. *Pulm Pharmacol Ther* 24: 100-109, 2011.
15. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ and Yuan JX: Cellular and molecular mechanisms of pulmonary vascular remodeling: Role in the development of pulmonary hypertension. *Microvasc Res* 68: 75-103, 2004.
16. Yamamoto M, Acevedo-Duncan M, Chalfant CE, Patel NA, Watson JE and Cooper DR: The roles of protein kinase C beta I and beta II in vascular smooth muscle cell proliferation. *Exp Cell Res* 240: 349-358, 1998.
17. Zhu BH, Yao ZX, Luo SJ, Jiang LM, Xiao JW, Liu SC, Liu JB, Sun JM and Pei ZY: Effects of antisense oligonucleotides of PKC- α on proliferation and apoptosis of HepG2 in vitro. *Hepatobiliary Pancreat Dis Int* 4: 75-79, 2005.
18. Sasaguri T, Kosaka C, Hirata M, Masuda J, Shimokado K, Fujishima M and Ogata J: Protein kinase C-mediated inhibition of vascular smooth muscle cell proliferation: The isoforms that may mediate G1/S inhibition. *Exp Cell Res* 208: 311-320, 1993.
19. Pisarcik S, Maylor J, Lu W, Yun X, Udem C, Sylvester JT, Semenza GL and Shimoda LA: Activation of hypoxia-inducible factor-1 in pulmonary arterial smooth muscle cells by endothelin-1. *Am J Physiol Lung Cell Mol Physiol* 304: L549-L561, 2013.
20. Li XW, Hu CP, Wu WH, Zhang WF, Zou XZ and Li YJ: Inhibitory effect of calcitonin gene-related peptide on hypoxia-induced rat pulmonary artery smooth muscle cells proliferation: Role of ERK1/2 and p27. *Eur J Pharmacol* 679: 117-126, 2012.
21. Ripple MO, Kim N and Springett R: Acute mitochondrial inhibition by mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) 1/2 inhibitors regulates proliferation. *J Biol Chem* 288: 2933-2940, 2013.
22. Preston IR, Hill NS, Warburton RR and Fanburg BL: Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. *Am J Physiol Lung Cell Mol Physiol* 290: L367-L374, 2006.
23. Li GW, Xing WJ, Bai SZ, Hao JH, Guo J, Li HZ, Li HX, Zhang WH, Yang BF and Wu LY: The calcium-sensing receptor mediates hypoxia-induced proliferation of rat pulmonary artery smooth muscle cells through MEK1/ERK1,2 and PI3K pathways. *Basic Clin Pharm Toxicol* 108: 185-193, 2011.
24. Wang P, Xu J, Hou Z, Wang F, Song Y, Wang J, Zhu H and Jin H: miRNA-34a promotes proliferation of human pulmonary artery smooth muscle cells by targeting PDGFRA. *Cell Prolif* 49: 484-493, 2016.
25. Barman SA, Zhu S and White RE: Protein kinase C inhibits BKCa channel activity in pulmonary arterial smooth muscle. *Am J Physiol Lung Cell Mol Physiol* 286: L149-L155, 2004.
26. Dempsey EC, Badesch DB, Dobyns EL and Stenmark KR: Enhanced growth capacity of neonatal pulmonary artery smooth muscle cells in vitro: Dependence on cell size, time from birth, insulin-like growth factor I, and auto-activation of protein kinase C. *J Cell Physiol* 160: 469-481, 1994.
27. Dempsey EC, Frid MG, Aldashev AA, Das M and Stenmark KR: Heterogeneity in the proliferative response of bovine pulmonary artery smooth muscle cells to mitogens and hypoxia: Importance of protein kinase C. *Can J Physiol Pharmacol* 75: 936-944, 1997.
28. Zhang HP, Xu YJ, Zhang ZX, Ni W and Chen SX: Effect of protein kinase C-nuclear factor-kappa B signal transduction pathway on proliferation and expression of vascular endothelial growth factor in human pulmonary artery smooth muscle cells. *Zhonghua Jie He He Hu Xi Za Zhi* 27: 218-223, 2004.
29. Jin N, Hatton N, Swartz DR, Xia X, Harrington MA, Larsen SH and Rhoades RA: Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. *Am J Respir Cell Mol Biol* 23: 593-601, 2000.
30. Weerackody RP, Welsh DJ, Wadsworth RM and Peacock AJ: Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. *Am J Physiol Heart Circ Physiol* 296: H1312-H1320, 2009.
31. Church AC, Martin DH, Wadsworth R, Bryson G, Fisher AJ, Welsh DJ and Peacock AJ: The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK- α : A potential novel anti-inflammatory strategy in pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* 309: L333-L347, 2015.
32. Sun Y, Tian Y, Prabha M, Liu D, Chen S, Zhang R, Liu X, Tang C, Tang X, Jin H and Du J: Effects of sulfur dioxide on hypoxic pulmonary vascular structural remodeling. *Lab Invest* 90: 68-82, 2010.
33. Xia S, Tai X, Wang Y, An X, Qian G, Dong J, Wang X, Sha B, Wang D, Murthi P, *et al*: Involvement of Gax gene in hypoxia-induced pulmonary hypertension, proliferation, and apoptosis of arterial smooth muscle cells. *Am J Respir Cell Mol Biol* 44: 66-73, 2011.
34. Zhang B, Shen M, Xu M, Liu LL, Luo Y, Xu DQ, Wang YX, Liu ML, Liu Y, Dong HY, *et al*: Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension. *Mediators Inflamm* 2012: 840737, 2012.
35. Park MJ, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Lee YS, Lee SH, Shim BS, *et al*: Protein kinase C- α activation by phorbol ester induces secretion of gelatinase B/MMP-9 through ERK 1/2 pathway in capillary endothelial cells. *Int J Oncol* 22: 137-143, 2003.
36. Okazaki J, Mawatari K, Liu B and Kent KC: The effect of protein kinase C and its alpha subtype on human vascular smooth muscle cell proliferation, migration and fibronectin production. *Surgery* 128: 192-197, 2000.